Investors Seek To Strike Part Of Pershing's Quick Win Bid

Investors behind a class action accusing Valeant Pharmaceuticals and hedge fund Pershing Square of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. urged a...

Already a subscriber? Click here to view full article